Evidence map›Paper›PMID 22935588›Full record

ArticleThe Journal of allergy and clinical immunology2012

Working with the US Food and Drug Administration: progress and timelines in understanding and treating patients with eosinophilic esophagitis.

Marc E Rothenberg, Seema Aceves, Peter A Bonis, Margaret H Collins, Nirmala Gonsalves, Sandeep K Gupta, Ikuo Hirano, Chris A Liacouras, Phil E Putnam, Jonathan M Spergel and 3 more

Abstract readEditorialComment
In one paragraph

Article in The Journal of allergy and clinical immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Scientific journey to the first FDA-approved drug for eosinophilic esophagitis.The Journal of allergy and clinical immunology · 2022
    Article
  5. Review
  6. Review
  7. A Conceptual Approach to Understanding Treatment Response in Eosinophilic Esophagitis.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2019
    Review
  8. Article
  9. Article
  10. White Paper AGA: Drug Development for Eosinophilic Esophagitis.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2017
    Review
  11. Article
  12. Eosinophilic Esophagitis: A Comprehensive Review.Clinical reviews in allergy & immunology · 2016
    Review
  13. Observational
  14. Systematic review of outcome measures in pediatric eosinophilic esophagitis treatment trials.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2016
    Article
  15. From genetics to treatment of eosinophilic esophagitis.Current opinion in allergy and clinical immunology · 2015
    Article
  16. Eosinophilic Esophagitis and Gastroenteritis.Current allergy and asthma reports · 2015
    Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Marc E Rothenberg
Seema Aceves
Peter A Bonis
Margaret H Collins
Nirmala Gonsalves
Sandeep K Gupta
Ikuo Hirano
Chris A Liacouras
Phil E Putnam
Jonathan M Spergel
Alex Straumann
Barry K Wershil
Glenn T Furuta

Funding

Regulation of Gastrointestinal EosinophilsR37AI045898 · NIAID · CINCINNATI CHILDRENS HOSP MED CTR · PI ROTHENBERG, MARC E. · 2010 to 2019
$3.6M
NIAID NIH HHS R37 AI045898
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Drug DiscoveryEosinophilic EsophagitisHumansRare Diseases

Identifiers

PMID22935588
PMCPMC3828675

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.